Prognostic value of Glypican family genes in early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy and possible mechanisms

Table 3 Joint effects analysis of combination of Glypican genes in The Cancer Genome Atlas database

Group	No. of events	MST (days)	Crude HR 95% CI	Crude P value	Adjusted HR 95% CI^a	Adjusted P value^a
GPC2 + GPC3
1	21/26(80.8%)	278	1	0.001	1	< 0.001
2	37/60(61.7%)	568	0.441(0.252–0.772)	0.004	0.350(0.187–0.653)	0.001
3	11/26(42.3%)	702	0.285(0.135–0.598)	0.001	0.173(0.072–0.418)	< 0.001
GPC2 + GPC5
I	18/23(78.3%)	278	1	0.001	1	< 0.001
II	40/66(60.6%)	517	0.424(0.237–0.758)	0.004	0.283(0.145–0.554)	< 0.001
III	11/23(47.8%)	702	0.253(0.116–0.552)	0.001	0.141(0.057–0.353)	< 0.001
GPC3 + GPC5
i	26/38(68.4%)	393	1	0.028	1	0.018
ii	21/36(58.3%)	498	0.685(0.383–1.226)	0.203	0.575(0292–1.129)	0.108
iii	22/38(57.9%)	691	0.443(0.243–0.805)	0.008	0.394(0.206–0.756)	0.005
GPC2 + GPC3 + GPC5
A	13/16(81.2%)	219	1	0.028	1	< 0.001
B	26/39(66.7%)	517	0.494(0.250–0.974)	0.042	0.446(0.212–0.938)	0.033
C	23/42(54.8%)	592	0.269(0.130–0.560)	< 0.001	0.176(0.076–0.406)	< 0.001
D	7/15(46.7%)	702	0.204(0.079–0.526)	0.001	0.135(0.045–0.403)	< 0.001

Group 1:low GPC2 + low GPC3; Group 2:low GPC2 + high GPC3 or high GPC2+ low GPC3; Group 3: high GPC2 + high GPC3
Group I:low GPC2 + low GPC5; Group II:low GPC2 + high GPC5 or high GPC2 + low GPC5; Group III: high GPC2 + high GPC5
Group i:low GPC3 + low GPC5; Group ii:low GPC3 + high GPC5 or high GPC3 + low GPC5; Group iii: high GPC3 + high GPC5
Group A:low GPC2 + low GPC3 + low GPC5; Group B: high GPC2 + low GPC3 + low GPC5 or low GPC2 + high GPC3 + low GPC5 or low GPC2 + low GPC3 + high GPC5; Group C:high GPC2 + high GPC3 + low GPC5 or high GPC2 + low GPC3 + high GPC5 or low GPC2 + high GPC3 + high GPC5; Group D:high GPC2 + high GPC3 + high GPC5
Abbreviations: MST median survival time, HR hazard ratio, CI confidence interval
^aAdjusted for histologic grade, targeted molecular therapy, radiation therapy and radical resection

ISSN: 1471-230X